Ask AI
ProCE Banner Events

Share

Acclimating Practice to the Current Treatment Landscape in FL: Emerging Evidence and Recent Results (Jan 26th)

Join us online for this live 1.5-hour, CME-certified Webinar to gain expert guidance on optimal management of relapsed/refractory follicular lymphoma. Experts will review the latest clinical data, including insights from the ASH 2022 annual meeting, along with discussing patient cases and answering audience questions.

maximum of 1.50 AMA PRA Category 1 Credits™

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for physicians and other healthcare professionals who care for patients with FL, including hematologists/oncologists, advanced care practitioners, pharmacists, and nurses.

Time and location

Thursday, January 26, 2023

12:00 PM - 1:30 PM Eastern Time (ET)

Virtual

Agenda

  • Welcome and Introduction
  • Overview of Relapsed/Refractory FL and Unmet Needs – Laurie Sehn, MD
  • Epigenetic Modifiers and PI3K Inhibitors – Ian Flinn, MD, PhD
  • Bispecific Antibodies – Laurie Sehn, MD
  • CAR T-Cell Therapy – Ian Flinn, MD, PhD
  • Final Panel Discussion and Audience Question and Answer Session

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of HCPs treating patients with relapsed/refractory follicular lymphoma by leveraging recent and emerging data that must be considered in treatment decisions.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Incorporate safety and efficacy data on novel and emerging therapies into management plans for patients with relapsed/refractory follicular lymphoma
  • Plan the optimal sequence of PI3K inhibitors, epigenetic modifiers, CAR T-cell therapy, and antibodies for patients with relapsed/refractory follicular lymphoma based on available evidence, as well as guideline and expert recommendations
  • Manage adverse events associated with novel treatment regimens in relapsed/refractory follicular lymphoma
  • Identify patients with relapsed/refractory follicular lymphoma who are eligible for enrollment on a clinical trial

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from:

Genentech, a member of the Roche Group
MEI Pharma, Inc. 

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.